Newsroom

OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash

View on PRNewswire SEATTLE, Jan. 4, 2024 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a leading targeted oncology supportive...

Jan 4, 2024

View on PRNewswire SEATTLE, June 6, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy...

Jun 6, 2023

View on PRNewswire SEATTLE, April 28, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Apr 28, 2023

View on PRNewswire SEATTLE, April 18, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Apr 18, 2023

View on PRNewswire SEATTLE, March 15, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Mar 15, 2023

View on PR Newswire SEATTLE, Jan. 5, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy...

Jan 5, 2023

View on PR Newswire SEATTLE, Nov. 8, 2022 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive...

Nov 8, 2022

Preclinical toxicology and pharmacology data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic...

Oct 14, 2022

View on PRNewswire - Preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment for...

May 27, 2022

- OnQuality will present preclinical data demonstrating OQL051, a gut-restricted CDK4/6 inhibitor, as a potential prophylactic treatment...

Mar 8, 2022